1. France Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
Novacyt S.A.

Novacyt S.A.

NCYT.L
Novacyt S.A.GB flagLondon Stock Exchange
34.75
GBp
-0.75
- -
25.17MMarket Cap
Novacyt S.A.
NCYT.L
(London Stock Exchange)

Recent

price

34.75

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
0.28
0.33
329.93
0.8
0.97
0.78
0.5
0.33
0.25
4.07
1.31
0.3
0.15
0.28
- -
Revenue per Share
-0.21
-0.17
-284.76
-0.69
-1.51
-0.4
-0.21
-0.11
-0.13
1.94
-0.14
-0.36
-0.4
-0.59
- -
Basic EPS, GAAP
-0.24
-0.24
-505.62
-0.47
-0.67
-0.22
-0.22
-0.05
-0.03
1.49
0.16
-0.2
-0.33
-0.16
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.17
-0.11
-1,173.91
-1.37
-2.36
-1.88
-1.21
-0.66
-0.72
1.48
1.29
0.93
0.48
-0.11
- -
Book Value per Share
-0.43
0.21
342.79
0.02
- -
-0.28
0.14
-0.02
-0.11
1.89
1.79
1.49
0.79
0.39
- -
Tangible Book Value per Share
3
3
- -
4
7
12
23
38
46
68
71
71
71
71
- -
Basic Weighted Avg Shares
1
1
1
4
7
9
11
12
11
277
93
21
11
20
20
Sales/Revenue/Turnover
-75.02
-51.94
-120.62
-53.16
-34.12
-26.97
-0.27
-3.8
-9.24
63.1
1.53
-74.5
-149.02
17.14
-61.8
Operating Margin (%)
- -
- -
- -
- -
7
1
1
1
2
8
8
8
10
- -
19
Depreciation Expense
-1
- -
-1
-3
-10
-5
-5
-4
-6
132
-10
-26
-28
-42
-23
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
19.83
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-74.93
-50.47
-86.31
-86.43
-156.41
-51.55
-42.69
-34.53
-50.13
47.77
-10.51
-122.29
-266.38
-212.73
-114.25
Profit Margin (%)
-1
1
1
1
1
-1
3
- -
- -
131
120
103
57
33
22
Working Capital
1
- -
- -
- -
2
2
1
2
8
2
1
- -
12
11
10
LT Debt
-1
1
2
16
8
15
22
18
12
151
142
115
87
48
23
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
135.89
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
334.73
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-10.12
-32.83
-56.9
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
105.59%
-29.05%
-51.19%
Free Cash Flow
-935.33%
-62.04%
-10.21%
Net Income, GAAP
-236.42%
13.9%
-45.2%
Sales/Revenue/Turnover
227.64%
-21.31%
2.03%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
11
2024
- -
- -
- -
- -
20
2025
- -
- -
- -
- -
20

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-0.4
2024
- -
- -
- -
- -
-0.59
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Surgalign Holdings, Inc. (SRGA)
Ion Beam Applications S.A. (IOBCF)
Profound Medical Corp. (PRN.TO)
Talis Biomedical Corporation (TLIS)
Qlife Holding AB (publ) (QLIFE.ST)
Acarix AB (publ) (ACIXF)
Business
Novacyt S.A. (NCYT.L) is an international molecular diagnostics company that develops, manufactures and commercialises molecular assays, instrumentation and workflows providing end-to-end solutions from sample to result in human health, animal health and environmental sectors; founded in 2006 and headquartered in Le Vésinet, France, with offices in the UK (Manchester, Eastleigh), Singapore, the US and Canada, and commercial presence in over 65 countries. The company operates three main segments offering clinical in vitro diagnostic products focused on reproductive health including non-invasive prenatal testing (NIPT), cystic fibrosis and rapid aneuploidy tests; precision medicine such as DPYD genotyping assays; infectious diseases with multiplex panels like Winterplex for respiratory pathogens; instrumentation encompassing Ranger Technology for automated DNA sample preparation and target enrichment, genesig q16/q32 and MyGo real-time qPCR instruments; and research use only assays plus services like whole genome/exome sequencing for human health, agriculture, veterinary and environmental applications. Subsidiaries include Primerdesign, specialising in qPCR kits and reagents since 2005, and Yourgene Health, providing NIPT NGS workflows, PCR assays and Ranger platforms for cfDNA applications in NIPT, liquid biopsy and oncology. In September 2023, Novacyt completed the strategic acquisition of Yourgene Health for £16.7 million, enhancing its reproductive health portfolio, global reach in Europe, Asia and the Americas, and delivering £5 million in cost synergies within 18 months; recent developments include site consolidations closing facilities in Vancouver and Stokesley while relocating operations to Manchester for £3 million annual EBITDA savings by end-2025, disposal of the Taiwanese laboratory business, support for a new NIPT service laboratory in Colombia operational since October 2024, appointment of Steve Gibson as CFO in January 2024, and product launches such as LightBench Discover in July 2025 for long-read sequencing, IONA Care+ NIPT service in February 2025, and planned four new products in 2025 across reproductive health, precision medicine and Ranger Technology backed by £2 million additional R&D investment.